Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Editorial] Age-related macular degeneration: treatment at what cost?

An estimated 8·4 million people worldwide have moderate to severe vision loss caused by age-related macular degeneration (AMD). A Seminar by Paul Mitchell and colleagues in today’s Lancet describes the latest developments in this devastating condition. The first symptoms of visual distortion or scotoma in one eye might indicate early-phase disease. Later stage AMD is classed as either wet, characterised by choroidal neovascularisation, or dry, characterised by atrophy. Beyond slowing disease progression with micronutrient supplementation, atrophic AMD has no treatment.

email